Table 1.
Demographic and clinical characteristics of the study population
NCSF group (n = 55) | CSF group (n = 71) | p | |
---|---|---|---|
Age | 55.73 ± 11.93 | 55.85 ± 11.06 | 0.954 |
Male | 34 (61.8%) | 60 (84.5%) | 0.004 |
BMI | 26.29 ± 4.97 | 27.15 ± 3.41 | 0.251 |
Smoking history | 24 (43.6%) | 45 (63.4%) | 0.021 |
Anti-platelet drugs | 30 (54.5%) | 36 (50.7%) | 0.402 |
β-blockers | 19 (34.5%) | 23 (32.4%) | 0.474 |
ACE inhibitors | 6 (10.9%) | 5 (7%) | 0.326 |
ARBs | 8 (14.5%) | 10 (14.1%) | 0.569 |
Statins | 26 (47.3%) | 31 (43.7%) | 0.411 |
Hypertension | 36 (65.5%) | 42 (59.2%) | 0.296 |
Diabetes | 13 (23.6%) | 10 (14.1%) | 0.276 |
LVEF | 64.11 ± 4.20 | 48.68 ± 4.16 | 0.264 |
LVEDd | 48.44 ± 4.33 | 48.68 ± 4.16 | 0.753 |
CAE in LAD (%) | 29 (52.7%) | 52 (73.2%) | 0.044 |
CAE in LCX (%) | 14 (25.5%) | 41 (57.7%) | 0.001 |
CAE in RCA (%) | 31 (56.4%) | 52 (73.2%) | 0.111 |
CAE in 1 vessel | 33 (60%) | 21 (29.6%) | 0.001 |
CAE in 2 vessels | 15 (27.3%) | 26 (36.6%) | 0.001 |
CAE in 3 vessels | 7 (12.7%) | 24 (33.8%) | 0.001 |